Melbourne, Australia, 09 January 2021: Certa Therapeutics is a biotechnology company focused on improving lives by developing innovative precision treatments for inflammatory and fibrotic diseases.
Certa Therapeuticsmanagement team including Chief Executive Officer, Professor Darren Kelly, will attend the 39th annual J.P. Morgan Healthcare Conference held from 11-14 January 2021.
As a result of the Covid-19 pandemic and subsequent travel restrictions, this year’s J.P. Morgan Healthcare Conference is being convened in a virtual format online.
“We’re pleased to attend this year’s virtual conference. Despite the change in format, we’re looking forward to continuing our discussions with J.P. Morgan and other biotechnology investment firms of the treatments we are developing to treat fibrosis,” said Professor Darren Kelly, CEO of Certa Therapeutics.
During the conference, the Certa team will highlight the progress it has made with clinical development program of a novel therapeutic platform of precision medicines for treating serious inflammatory and fibrotic diseases including systemic sclerosis (SSc) and chronic kidney disease (CKD).
SSc is a rare autoimmune disease, causing inflammation and fibrosis (scarring/hardening) of the skin and other organs. There is a clear need for new innovative treatments as currently approved therapies are largely ineffective and can have significant side-effects.
There are currently no treatments available for kidney fibrosis, which presents in the majority of patients with CKD. Given the enormous cost of dialysis and kidney transplants to the healthcare system, finding an effective treatment for these patients remains one of the global healthcare industry’s largest unmet needs.
The premier conference is the largest and most informative healthcare investment symposium in the industry which connects global industry leaders, emerging fast-growth companies, innovative technology creators and members of the investment community.